Company profile: AIM ImmunoTech
1.1 - Company Overview
Company description
- Provider of immuno-pharmaceutical therapeutics centered on Ampligen, an immuno-modulator evaluated for cancer, immunodeficiency disorders and viral diseases, and approved in Argentina for severe chronic fatigue syndrome. Operates an Early Access Program in the Netherlands for pancreatic cancer, runs Phase 2 and combinational therapy trials in solid tumors, and studies ME/CFS and post-COVID conditions.
Products and services
- Ampligen®: An investigational immuno-modulator evaluated for cancer, immunodeficiency disorders, and viral diseases, and approved in Argentina for severe chronic fatigue syndrome
- Clinical trials for solid tumor types: Ongoing combinational studies architected at major research centers to evaluate Ampligen alongside other therapies across various solid tumor cancers
- Early Access Program (EAP) for pancreatic cancer: Netherlands Phase 2 program employing Ampligen to treat pancreatic cancer patients, including a clinical study in locally advanced pancreatic cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AIM ImmunoTech
Tetraphase Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for significant disease categories, including GIAPREZA to increase blood pressure in adults with septic or other distributive shock; XERAVA for complicated intra-abdominal infections in adults; XACDURO for hospital- and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex; and investigational zoliflodacin for uncomplicated gonorrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetraphase Pharmaceuticals company profile →
Abivax
HQ: France
Website
- Description: Provider of clinical-stage biotechnology therapies that mobilize the body's natural immune machinery to treat autoimmune diseases, viral infections, and cancer, including obefazimod for ulcerative colitis (Phase 3), planned Phase 2b for Crohn's disease, exploration as combination therapy for ulcerative colitis in preclinical studies, and nonclinical evaluation for additional chronic inflammatory indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abivax company profile →
Spectrum Antimicrobials
HQ: United States
Website
- Description: Provider of pharmaceutical drug development specializing in antibiotics and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectrum Antimicrobials company profile →
Sherlock Biosciences
HQ: United States
Website
- Description: Provider of engineering biology-based molecular diagnostics leveraging CRISPR and synthetic biology, including SHERLOCK for DNA/RNA detection and INSPECTR for instrument-free ambient tests, plus an FDA-authorized CRISPR SARS-CoV-2 kit. Offers global health partnerships to develop and distribute affordable infectious disease diagnostics and an internship & co-op program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sherlock Biosciences company profile →
Lumora
HQ: United Kingdom
Website
- Description: Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumora company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AIM ImmunoTech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AIM ImmunoTech
2.2 - Growth funds investing in similar companies to AIM ImmunoTech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AIM ImmunoTech
4.2 - Public trading comparable groups for AIM ImmunoTech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →